Compare Advance Auto Parts, Inc. (AAP) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Enveric Biosciences Inc — how do they compare? Advance Auto Parts, Inc. trades at $52.93 (market cap $3.36B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Advance Auto Parts, Inc. is far larger — about 541.9× Enveric Biosciences Inc's market cap, and Advance Auto Parts, Inc. pays a 1.79% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| AAP | ENVB | |
|---|---|---|
Market Cap | $3.36B | $6.20M |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $17.40 |
52-Week Low | $38.75 | $1.27 |
Enterprise Value | $5.63B | $1.30M |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $57.80, down 0.21% on the day, with a bullish technical signal and key support at $57. The company shows mixed fundamentals: a low P/S of 0.41 and strong recent earnings beats, but thin net margins of 0.51% and negative operating cash flow in 2025. News highlights restructuring efforts and AI-driven delivery initiatives as potential growth catalysts.
The outlook is cautiously optimistic; analyst consensus targets $61.30 with a buy rating, but high debt and competitive pressures pose risks. Earnings momentum and valuation appeal offer upside, yet execution on turnaround plans is critical for sustained recovery.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
